235 lines
50 KiB
HTML
235 lines
50 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
|
||
<meta charset="utf-8"/>
|
||
<meta content="pandoc" name="generator"/>
|
||
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
|
||
<title>13 June, 2021</title>
|
||
<style type="text/css">
|
||
code{white-space: pre-wrap;}
|
||
span.smallcaps{font-variant: small-caps;}
|
||
span.underline{text-decoration: underline;}
|
||
div.column{display: inline-block; vertical-align: top; width: 50%;}
|
||
</style>
|
||
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
||
<body>
|
||
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
||
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
||
<ul>
|
||
<li><a href="#from-preprints">From Preprints</a></li>
|
||
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
||
<li><a href="#from-pubmed">From PubMed</a></li>
|
||
<li><a href="#from-patent-search">From Patent Search</a></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
||
<ul>
|
||
<li><strong>Early evidence for the safety of certain COVID-19 vaccines using empirical Bayesian modeling from VAERS</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
The advent of vaccines against SARS-CoV-2 ushered in an unprecedented global response to COVID-19, with the largest and most ambitious mass vaccination campaign in human history. The scale of this effort means that safety signals suggesting adverse effects may only be detectable using passive reporting. This paper examines reports to the CDC/FDA9s VAERS system in the first six months of 2021, using an empirical Bayesian model with a gamma Poisson shrinker to identify potential safety signals from COVID-19 vaccines currently on the U.S. market. Based on this preliminary data, it is concluded that the COVID-19 vaccine9s safety significantly exceeds that of previously marketed vaccines, and other than a known risk of thrombotic events, no safety signals of concern emerge.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.06.10.21258589v1" target="_blank">Early evidence for the safety of certain COVID-19 vaccines using empirical Bayesian modeling from VAERS</a>
|
||
</div></li>
|
||
<li><strong>Comprehensive characterization of COVID-19 patients with repeatedly positive SARS-CoV-2 tests using a large US electronic health record database</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background: In the absence of genome sequencing, two positive molecular SARS-CoV-2 tests separated by negative tests, prolonged time, and symptom resolution remain the best surrogate measure of possible re-infection. Methods: Using a large electronic health record database, we characterized clinical and testing data for 23 patients with repeatedly positive SARS-CoV-2 PCR test results >60 days apart, separated by >2 consecutive negative test results. Prevalence of chronic medical conditions, symptoms and severe outcomes related to COVID-19 illness were ascertained. Results: Median age was 64.5 years, 40% were Black, and 39% were female. 83% smoked within the prior year, 61% were overweight/obese, 83% had immune compromising conditions, and 96% had >2 comorbidities. Median interval between the two positive tests was 77 days. Among the 19 patients with 60-89 days between positive tests, 17 (89%) exhibited symptoms or clinical manifestations indicative of COVID-19 at the time of the second positive test and 14 (74%) were hospitalized at the second positive test. Of the four patients with >90 days between two positive tests, two had mild or no symptoms at the second positive test and one, an immune compromised patient, had a brief hospitalization at the first diagnosis, followed by ICU admission at the second diagnosis three months later. Conclusions: Our study demonstrated a high prevalence of immune compromise, comorbidities, obesity and smoking among patients with repeatedly positive SARS-CoV-2 tests. Despite limitations, including lack of semi-quantitative estimates of viral load, these data may help prioritize suspected cases of reinfection for investigation and continued surveillance.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.06.10.21256915v1" target="_blank">Comprehensive characterization of COVID-19 patients with repeatedly positive SARS-CoV-2 tests using a large US electronic health record database</a>
|
||
</div></li>
|
||
<li><strong>SARS-COV-2 VIRUS INFECTED PATIENT IDENTIFICATION THROUGH CANINE OLFACTIVE DETECTION ON AXILLARY SWEAT SAMPLES</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Facing the COVID-19 pandemic, testing individuals in order to promptly isolate positive people is one of the key actions. One approach to rapid testing might be to consider the olfactory capacities of trained detection dogs in order to develop a non-invasive, rapid and cheap mass detection approach, through the Volatile Organic Compounds (VOCs) signature of SARS-CoV-2 infection. The goal of this study is to determine the individual values of sensitivity and specificity of trained dogs when performing olfactory detection of COVID-19 on axillary sweat samples. A group of 7 dogs was tested on a total of 218 samples (62 positive and 156 negative), completely unknown to the dogs, following a randomised and double-blinded protocol carried out on olfaction cone line-ups. To ensure a wide olfactory range as close as possible to operational conditions, the samples were retrieved from 13 different sites. Sensitivities vary from 87 to 94p100 for 6 dogs, and are above 90p100 for 3 of them. Only one dog, whose sensitivity was 60p100, was not selected to continue the study and enter the operational stage. Sensitivity results vary from 78 to 92p100, with 6 dogs over 85p100 and 4 over 90p100. Thanks to these results, a virtual approach of Positive and Negative Predilection Values (PPV and NPV) was designed, based on an almost perfect diagnostic tool as reference and for increasing prevalence values of SARS-CoV-2 infection. The studies to come on olfactory detection of COVID-19 by dogs will still face several challenges, but the accumulation of positive and encouraging results suggest that it may play an important part in mass COVID-19 pre-testing situations.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.06.10.21257898v1" target="_blank">SARS-COV-2 VIRUS INFECTED PATIENT IDENTIFICATION THROUGH CANINE OLFACTIVE DETECTION ON AXILLARY SWEAT SAMPLES</a>
|
||
</div></li>
|
||
<li><strong>SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background Following a year of development, several vaccines have been approved to contain the global COVID-19 pandemic. Real world comparative data on immune response following vaccination or natural infection are rare. Methods We conducted a longitudinal observational study in employees at a secondary care hospital affected by the COVID-19 pandemic. Comparisons were made about the presence of anti-SARS-CoV-2 immunglobulin G (IgG) antibody ratio after natural infection, or vaccination with one or two doses of BioNTech/Pfizer (BNT162b2), or one dose of AstraZenca (Vaxzevria) vaccine. Results We found a 100% humoral response rate in participants after 2 doses of BNT162b2 vaccine. The antibody ratio in participants with one dose BNT162b2 and Vaxzevria did not differ significantly to those with previous PCR-confirmed infection, whereas this was significantly lower in comparison to two doses of BioNTech/Pfizer. We could not identify a correlation with previous comorbidities, obesity or age within this study. Smoking showed a negative effect on the antibody response (p=0.006) Conclusion Our data provide an overview about humoral immune response after natural SARS-CoV-2 infection or following vaccination, and supports the usage of booster vaccinations, especially in patients after a natural SARS-CoV-2 infection.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.06.09.21258648v1" target="_blank">SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study</a>
|
||
</div></li>
|
||
<li><strong>Modeling and reviewing analysis of the COVID-19 epidemic in Algeria with diagnostic shadow</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
In this paper, we formulate a special epidemic dynamic model to describe the transmission of COVID-19 in Algeria. We derive the threshold parameter control reproduction number (R0c ), and present the effective control reproduction number (Rc(t)) as a real-time index for evaluating the epidemic under different control strategies. Due to the limitation of the reported data, we redefine the number of accumulative confirmed cases with diagnostic shadow and then use the processed data to do the optimal numerical simulations. According to the control measures, we divide the whole research period into six stages. And then the corresponding medical resource estimations and the average effective control reproduction numbers for each stage are given. Meanwhile, we use the parameter values which are obtained from the optimal numerical simulations to forecast the whole epidemic tendency under different control strategies.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.06.09.21258668v1" target="_blank">Modeling and reviewing analysis of the COVID-19 epidemic in Algeria with diagnostic shadow</a>
|
||
</div></li>
|
||
<li><strong>Seasonal variation in SARS-CoV-2 transmission in temperate climates</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
While seasonal variation has a known influence on the transmission of several respiratory viral infections, its role in SARS-CoV-2 transmission remains unclear. As previous analyses have not accounted for the implementation of non-pharmaceutical interventions (NPIs) in the first year of the pandemic, they may yield biased estimates of seasonal effects. Building on two state-of-the-art observational models and datasets, we adapt a fully Bayesian method for estimating the association between seasonality and transmission in 143 temperate European regions. We find strong seasonal patterns, consistent with a reduction in the time-variable Rt of 42.1% (95% CI: 24.7% - 53.4%) from the peak of winter to the peak of summer. These results imply that the seasonality of SARS-CoV-2 transmission is comparable in magnitude to the most effective individual NPIs but less than the combined effect of multiple interventions.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.06.10.21258647v1" target="_blank">Seasonal variation in SARS-CoV-2 transmission in temperate climates</a>
|
||
</div></li>
|
||
<li><strong>Second wave of COVID-19 in India could be predicted with genomic surveillance of SARS-CoV-2 variants coupled with epidemiological data: A tool for future</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
India has witnessed a devastating second wave of COVID-19, which peaked during the last week of April and the second week of May, 2021. We aimed to understand whether the arrival of second wave was predictable and whether it was driven by the existing SARS-CoV-2 strains or any of the emerging variants. We analyzed the monthly distribution of the genomic sequence data for SARS-CoV-2 from India and correlated that with the epidemiological data for new cases and deaths, for the corresponding period of the second wave. Our analysis shows that the first indications of arrival of the second wave were observable by January, 2021, and by March, 2021 it was clearly predictable. B.1.617 lineage variants drove the wave, particularly B.1.617.2 (a.k.a. delta variant). We propose that genomic surveillance of the SARS-CoV-2 variants augmented with epidemiological data can be a promising tool for predicting future COVID-19 waves.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.06.09.21258612v2" target="_blank">Second wave of COVID-19 in India could be predicted with genomic surveillance of SARS-CoV-2 variants coupled with epidemiological data: A tool for future</a>
|
||
</div></li>
|
||
<li><strong>Estimating the elevated transmissibility of the B.1.1.7 strain over previously circulating strains in England using GISAID sequence frequencies</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
The B.1.1.7 strain, also referred to as Alpha variant, is a variant strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Alpha variant is considered to possess higher transmissibility compared to the strains previously circulating in England. This paper proposes a new method to estimate the selective advantage of a mutant strain over another strain using the time course of strain frequencies and the distribution of the serial interval of infections. This method allows the instantaneous reproduction numbers of infections to vary over calendar time. The proposed method also assumes that the selective advantage of a mutant strain over previously circulating strains is constant. Applying the method to SARS-CoV-2 sequence data from England, the instantaneous reproduction number of the B.1.1.7 strain was estimated to be 26.6-45.9% higher than previously circulating strains in England. This result indicates that control measures should be strengthened by 26.6-45.9% when the B.1.1.7 strain is newly introduced to a country where viruses with similar transmissibility to the preexisting strain in England are predominant.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.03.17.21253775v4" target="_blank">Estimating the elevated transmissibility of the B.1.1.7 strain over previously circulating strains in England using GISAID sequence frequencies</a>
|
||
</div></li>
|
||
<li><strong>The use of digitalization for micro, small and medium enterprises</strong> -
|
||
<div>
|
||
As we know, the Indonesian economy experienced a deflation of 0.1% in July 2020. This occurred in the food, beverage and tobacco category, which experienced a deflation of 0.79%. and contributed 0.19% to deflation. Foodstuffs that contributed to deflation included shallots, free-range chicken, rice, garlic, cayenne pepper, and sugar. Deflation in July and August 2020 was triggered more by falling prices for a number of food, beverages, and transportation, increasing demand amid the Covid-19 pandemic. Trends in other countries show that inflation and deflation are beating supply and demand. in 4 countries such as Indonesia, the Philippines, Thailand and Laos involving 3,831 MSME respondents explained that the contribution of MSMEs to Gross Domestic Product in these 4 countries was more than 50%. The enactment of the region had a negative impact on MSMEs, but some MSMEs continued to operate despite experiencing a decline in income of more than 40%.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/258gj/" target="_blank">The use of digitalization for micro, small and medium enterprises</a>
|
||
</div></li>
|
||
<li><strong>Performance Impact of e-business use in Indonesian Small and Medium Enterprises (SMEs)</strong> -
|
||
<div>
|
||
A new business platform is a must for companies that are disrupting new media technology, especially during the Covid 19 era. However, many incumbent companies are less able to keep up with changing business trends. Anticipate all changes in the competitive climate in the digital era in carrying out the company transformation program along with the implementation of good corporate governance values to avoid oral hazards and a greater risk of failure. proposes an integrated framework that investigates interrelationships between contextual factors that influence e-business use and consequently its impact on enterprise performance among small and medium enterprises (SMEs).
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/m6rsa/" target="_blank">Performance Impact of e-business use in Indonesian Small and Medium Enterprises (SMEs)</a>
|
||
</div></li>
|
||
<li><strong>Maximizing the Role of Digital Platforms for Medium, Small and Medium Enterprises</strong> -
|
||
<div>
|
||
The role of MSMEs is big for the Indonesian economy. The government should help MSMEs to developed themselves during the Covid-19 pandemic. The best thing to do is to maximize the role of digital platforms for MSMEs so that they can collaborate with online platforms and increasing their sales.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/vtukh/" target="_blank">Maximizing the Role of Digital Platforms for Medium, Small and Medium Enterprises</a>
|
||
</div></li>
|
||
<li><strong>The effects of non-pharmaceutical interventions on COVID-19-related mortality: A generalized synthetic control approach across 169 countries</strong> -
|
||
<div>
|
||
Background: Most governments have introduced various non-pharmaceutical interventions (NPIs) in response to the pandemic outbreak of Coronavirus disease (COVID-19) since early 2020. While NPIs aim at avoiding fatalities related to COVID-19, the previous literature on their efficacy has focused on infections and on data of the first half of 2020. Still, findings of early NPI studies may be subject to underreporting and missing timeliness of reporting of cases. Moreover, the low variation in treatment timing during the first wave makes identification of robust treatment effects difficult. Methods: To circumvent problems of reporting and treatment variation, we analyse data on daily confirmed COVID-19-related deaths per capita from Our World in Data, and on 10 different NPIs from the Oxford COVID-19 Government Response Tracker for 169 countries from 1st July 2020 to 31st May 2021. To identify the causal effects of introducing NPIs on COVID-19-related confirmed fatalities per capita, we apply the generalized synthetic control (GSC) method to each NPI, while controlling for the remaining NPIs, weather conditions, vaccinations, and NPI-residualized COVID-19 cases. Findings: We do not find substantial and consistent mitigating effects of any NPI under investigation on COVID-19-related deaths per capita. We see a tentative change in the trend of COVID-19-related deaths around 30 days after workplace closing, public transport closing, and stay at home rules have been implemented, but none of them exerts a statistically significant effect. Interpretation: The study enhances the literature on the effectivity of NPIs with respect to the time frame, the number of countries, and the analytical approach. The results provide further guidance to judge the proportionality of NPIs.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/v2ef8/" target="_blank">The effects of non-pharmaceutical interventions on COVID-19-related mortality: A generalized synthetic control approach across 169 countries</a>
|
||
</div></li>
|
||
<li><strong>Performance Impact of e-business use in Indonesian Small and Medium Enterprises (SMEs)</strong> -
|
||
<div>
|
||
A new business platform is a must for companies that are disrupting new media technology, especially during the Covid 19 era. However, many incumbent companies are less able to keep up with changing business trends. Anticipate all changes in the competitive climate in the digital era in carrying out the company transformation program along with the implementation of good corporate governance values to avoid oral hazards and a greater risk of failure. proposes an integrated framework that investigates interrelationships between contextual factors that influence e-business use and consequently its impact on enterprise performance among small and medium enterprises (SMEs).
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/mdhfx/" target="_blank">Performance Impact of e-business use in Indonesian Small and Medium Enterprises (SMEs)</a>
|
||
</div></li>
|
||
<li><strong>Alpha-ketoglutarate augments prolyl hydroxylase-2 mediated inactivation of phosphorylated-Akt to inhibit induced-thrombosis and inflammation</strong> -
|
||
<div>
|
||
Phosphorylation of Akt (pAkt) regulates multiple physiological and pathological processes including thrombosis and inflammation. In an approach to inhibit the pathological signalling of pAkt by prolyl-hydroxylase-2 (PHD2) we employed alpha-ketoglutarate (AKG), a cofactor of PHD2. Octyl-AKG supplementation to platelets promoted PHD2 activity through elevated intracellular AKG:succinate ratio and reduced aggregation in vitro by suppressing pAkt1(Thr308). Augmented PHD2 activity was confirmed by increased hydroxylated-proline alongside enhanced binding of PHD2 to pAkt in AKG-treated platelets. Contrastingly, inhibitors of PHD2 significantly increased pAkt1 in platelets. Octyl-AKG followed similar mechanism in monocytes to inhibit cytokine secretion in vitro. Our data also describe a suppressed pAkt1 and reduced activation of platelet and leukocyte obtained from mice supplemented with dietary-AKG, unaccompanied by alteration in their counts. Dietary-AKG significantly reduced clot formation and leukocyte accumulation in various organs including lung of mice treated with thrombosis-inducing agent carrageenan. Importantly, we observed a significant rescue effect of dietary-AKG on inflamed lung of SARS-CoV-2 infected hamsters. AKG significantly reduced leukocyte accumulation, clot formation and viral load alongside downmodulation of pAkt in lung of the infected animals. Therefore, our study suggests a safe implementation of dietary-AKG in prevention of Akt-driven anomalies including thrombosis and inflammation, highlighting a better pulmonary management in COVID-19.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.06.11.448037v1" target="_blank">Alpha-ketoglutarate augments prolyl hydroxylase-2 mediated inactivation of phosphorylated-Akt to inhibit induced-thrombosis and inflammation</a>
|
||
</div></li>
|
||
<li><strong>The effect of obesity-related traits on COVID-19 severe respiratory symptoms is mediated by socioeconomic status: a multivariable Mendelian randomization study</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background Obesity has been associated with more severe clinical manifestations of coronavirus disease 2019 (COVID-19). However, this association can be affected by many correlates of these traits. Due to its large impact on human health, socioeconomic status (SES) could at least partially influence the association between obesity and COVID-19 severity. To estimate the independent effect of traits related to body size and SES on the clinical manifestations of COVID-19, we conducted a Mendelian randomization (MR) study analyzing the effect of obesity-related anthropometric traits on COVID-19 outcomes. Methods Applying two-sample MR approaches, we evaluated the effects of body mass index (BMI), waist circumference (WC), hip circumference, (HIP) and waist-hip ratio (WHR) studied in up to 234,069 participants from the Genetic Investigation of ANthropometric Traits (GIANT) consortium with respect to three COVID-19 outcomes: severe respiratory COVID-19 (5,101 cases vs. 1,383,241 controls), hospitalized COVID-19 (9,986 cases vs. 1,877,672 controls), and COVID-19 infection (38,984 cases vs. 1,644,784 controls) obtained from the COVID-19 Host Genetics Initiative (HGI). Finally, to test the effect of SES using multivariable MR methods, we analyzed genetic data related to self-reported household income (HI) information from 286,301 UK Biobank (UKB) participants. Results BMI and WC were associated with severe respiratory COVID-19 (BMI: OR = 1.68 p = 0.0004; WC: OR = 1.72, p = 0.007) and COVID-19 hospitalization (BMI: OR= 1.62, p = 1.35e-06; WC: OR = 1.62, p = 0.0001). Also, HIP influenced hospitalized COVID-19 (OR = 1.31, p = 0.012) and COVID-19 infection (OR = 1.18, p = 0.002). Conversely, HI was associated with lower odds of severe respiratory COVID-19 (OR = 0.57, p = 0.011) and hospitalized COVID-19 (OR = 0.71, p = 0.045). Testing these effects in multivariable MR models, we observed that the effect of these obesity-related anthropometric traits on COVID-19 outcomes is not independent of SES effect assessed as HI. Conclusions Our findings indicate that low SES is a contributor to the observed association between body size and COVID-19 outcomes.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.06.08.21258587v1" target="_blank">The effect of obesity-related traits on COVID-19 severe respiratory symptoms is mediated by socioeconomic status: a multivariable Mendelian randomization study</a>
|
||
</div></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ivermectin Treatment Efficacy in Covid-19 High Risk Patients</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Drug: Ivermectin 0.4mg/kg/day for 5 days<br/><b>Sponsor</b>: Clinical Research Centre, Malaysia<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Drug: Black Seed Oil Cap/Tab<br/><b>Sponsor</b>: Novatek Pharmaceuticals<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 “Long Haul” Pulmonary Compromise</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Biological: COVI-MSC<br/><b>Sponsor</b>: Sorrento Therapeutics, Inc.<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Intramuscular VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Biological: VIR-7831<br/><b>Sponsors</b>: Vir Biotechnology, Inc.; GlaxoSmithKline<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nervous System Symptoms Associated With COVID 19</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Other: NEURO +; Other: NEURO -<br/><b>Sponsor</b>: University Hospital, Toulouse<br/><b>Completed</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Collecting Respiratory Sound Samples From Corona Patients to Extend the Diagnostic Capability of VOQX Electronic Stethoscope to Diagnose COVID-19 Patients</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Diagnostic Test: Electronic stethoscope<br/><b>Sponsor</b>: Sanolla<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Burden of COVID-19 Survivorship</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Other: Exercise Training<br/><b>Sponsor</b>: Mayo Clinic<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Community-based Post-exposure Prophylaxis for COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Other: Guduchi Ghanvati; Other: Standard guidelines<br/><b>Sponsors</b>: NMP Medical Research Institute; Aarogyam UK; Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University; Samta Ayurveda Prakoshtha, India; Padmanabhama Ayurveda Hospital and Research Centre<br/><b>Completed</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Impact of Steroids on Inflammatory Response in Covid-19</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Drug: Dexamethasone; Drug: Methylprednisolone<br/><b>Sponsor</b>: Assiut University<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vitamin A Supplementation in Children With Moderate to Severe Covid-19</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Dietary Supplement: Vitamin A supplement<br/><b>Sponsor</b>: Shiraz University of Medical Sciences<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Device: PneumoniaCheck<br/><b>Sponsors</b>: Emory University; Georgia Tech Foundation<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Glutamine Supplementation and Short-term Mortality in Covid-19</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Dietary Supplement: Standard enteral nutrition; Combination Product: Glutamine<br/><b>Sponsor</b>: Assiut University<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Drug: Favipiravir; Drug: Nitazoxanide; Other: Nitazoxanide Placebo<br/><b>Sponsors</b>: Coordinación de Investigación en Salud, Mexico; University College, London; Centro de Investigacion y Estudios Avanzados del Instituto Politecnico Nacional (CINVESTAV); Universidad Autonoma de Guadalajara; Siegfried Rhein S.A. de C.V.; Strides Pharma Science Limited; Hakken Enterprise<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Epidemiologic Intelligence Network (EpI-Net) to Promote COVID-19 Testing</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Other: Epi-Net Intervention<br/><b>Sponsors</b>: Ponce Medical School Foundation, Inc.; Duke University; Harvard School of Public Health<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Biological: Dupilumab; Drug: Placebo<br/><b>Sponsors</b>: University of Virginia; PBM C19 Research, LLC (PBM); Virginia Catalyst, Virginia Biosciences Health Research Corporation (VBHRC)<br/><b>Recruiting</b></p></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Positive Selection as a Key Player for SARS-CoV-2 Pathogenicity: Insights into ORF1ab, S and E genes</strong> - The human β-coronavirus SARS-CoV-2 epidemic started in late December 2019 in Wuhan, China. It causes Covid-19 disease which has become pandemic. Each of the five-known human β-coronaviruses has four major structural proteins (E, M, N and S) and 16 non-structural proteins encoded by ORF1a and ORF1b together (ORF1ab) that are involved in virus pathogenicity and infectivity. Here, we performed detailed positive selection analyses for those six genes among the four previously known human…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Molecular mechanism of anti-SARS-CoV2 activity of Ashwagandha-derived withanolides</strong> - COVID-19 caused by SARS-CoV-2 corona virus has become a global pandemic. In the absence of drugs and vaccine, and premises of time, efforts and cost required for their development, natural resources such as herbs are anticipated to provide some help and may also offer a promising resource for drug development. Here, we have investigated the therapeutic prospective of Ashwagandha for the COVID-19 pandemic. Nine withanolides were tested in silico for their potential to target and inhibit (i) cell…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Global analysis of protein-RNA interactions in SARS-CoV-2-infected cells reveals key regulators of infection</strong> - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 relies on cellular RNA-binding proteins (RBPs) to replicate and spread, although which RBPs control its life cycle remains largely unknown. Here, we employ a multi-omic approach to identify systematically and comprehensively the cellular and viral RBPs that are involved in SARS-CoV-2 infection. We reveal that SARS-CoV-2 infection profoundly remodels the cellular RNA-bound proteome,…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 mRNA vaccination generates greater IgG levels in women compared to men</strong> - QUESTION: Is antibody response to COVID-19 mRNA vaccination similar in women and men?</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Interaction of selected terpenoids with two SARS-CoV-2 key therapeutic targets: An in silico study through molecular docking and dynamics simulations</strong> - The outbreak of COVID-19 disease caused by SARS-CoV-2, along with the lack of targeted medicaments, forced the scientific world to search for new antiviral formulations. In the current emergent situation, drug repurposing of well-known traditional and/or approved drugs could be the most effective strategy. Herein, through computational approaches, we aimed to screen 14 natural compounds from limonoids and terpenoids class for their ability to inhibit the key therapeutic target proteins of…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation</strong> - Acute respiratory distress syndrome (ARDS), an inflammatory condition with high mortality rates, is common in severe COVID-19, whose risk is reduced by metformin rather than other anti-diabetic medications. Detecting of inflammasome assembly in post-mortem COVID-19 lungs, we asked whether and how metformin inhibits inflammasome activation while exerting its anti-inflammatory effect. We show that metformin inhibited NLRP3 inflammasome activation and interleukin (IL)-1β production in cultured and…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target</strong> - Cytokine storm and multi-organ failure are the main causes of SARS-CoV-2-related death. However, the origin of excessive damages caused by SARS-CoV-2 remains largely unknown. Here we show that the SARS-CoV-2 envelope (2-E) protein alone is able to cause acute respiratory distress syndrome (ARDS)-like damages in vitro and in vivo. 2-E proteins were found to form a type of pH-sensitive cation channels in bilayer lipid membranes. As observed in SARS-CoV-2-infected cells, heterologous expression of…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>I(nsp1)ecting SARS-CoV-2-ribosome interactions</strong> - While SARS-CoV-2 is causing modern human history’s most serious health crisis and upending our way of life, clinical and basic research on the virus is advancing rapidly, leading to fascinating discoveries. Two studies have revealed how the viral virulence factor, nonstructural protein 1 (Nsp1), binds human ribosomes to inhibit host cell translation. Here, we examine the main conclusions on the molecular activity of Nsp1 and its role in suppressing innate immune responses. We discuss different…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19</strong> - CONCLUSION: Collectively, such macrophage biomimetic nanocarriers based drug delivery system showed favorable anti-inflammation and targeted antiviral effects, which may possess a comprehensive therapeutic value in COVID-19 treatment.</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vitamin D attenuates COVID-19 complications via modulation of proinflammatory cytokines, antiviral proteins, and autophagy</strong> - Introduction: Global emergence of coronavirus disease-19 (COVID-19) has clearly shown variable severity, mortality, and frequency between and within populations worldwide. These striking differences have made many biological variables attractive for future investigations. One of these variables, vitamin D, has been implicated in COVID-19 with rapidly growing scientific evidence. Areas covered: The review intended to systematically explore the sources, and immunomodulatory the role of vitamin D…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2)</strong> - The recent emergence of the novel coronavirus (SARS-CoV-2) has resulted in a devastating pandemic with global concern. However, to date, there are no regimens to prevent and treat SARS-CoV-2 virus. There is an urgent need to identify novel leads with anti-viral properties that impede viral pathogenesis in the host system. Esculentoside A (EsA), a saponin isolated from the root of Phytolacca esculenta, is known to exhibit diverse pharmacological properties, especially anti-inflammatory activity….</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy and safety of Dihydroorotate dehydrogenase (DHODH) inhibitors “Leflunomide” and “Teriflunomide” in Covid-19: A narrative review</strong> - Dihydroorotate dehydrogenase (DHODH) is rate-limiting enzyme in biosynthesis of pyrimidone which catalyzes the oxidation of dihydro-orotate to orotate. Orotate is utilized in the biosynthesis of uridine-monophosphate. DHODH inhibitors have shown promise as antiviral agent against Cytomegalovirus, Ebola, Influenza, Epstein Barr and Picornavirus. Anti-SARS-CoV-2 action of DHODH inhibitors are also coming up. In this review, we have reviewed the safety and efficacy of approved DHODH inhibitors…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Therapeutic targets of natural products for the management of cardiovascular symptoms of coronavirus disease 2019</strong> - The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first occurred in China in December 2019 and subsequently spread all over the world with cardiovascular, renal, and pulmonary symptoms. Therefore, recognizing and treating the cardiovascular sign and symptoms that caused by coronavirus disease 2019 (COVID-19) can be effective in reducing patient mortality. To control the COVID-19-related cardiovascular symptoms, natural products are considered one of the promising…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors</strong> - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. While previous studies have shown that several SARS-CoV-2 proteins can antagonize the interferon (IFN) response, some of the mechanisms by which they do so are not well understood. In this study, we describe two novel mechanisms by which SARS-CoV-2 blocks the IFN pathway. Type I IFNs and IFN-stimulated genes (ISGs) were poorly induced during SARS-CoV-2…</p></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>폐마스크 밀봉 회수기</strong> - 본 발명은 마스크 착용 후 버려지는 일회용 폐마스크를 비닐봉지에 넣은 후 밀봉하여 배출함으로써, 2차 감염을 예방하고 일반 생활폐기물과 선별 분리 배출하여 환경오염을 방지하는 데 그 목적이 있다. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=KR325788342">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COST EFFECTIVE PORTABLE OXYGEN CONCENTRATOR FOR COVID-19</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU324964715">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>METHOD OF IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA)</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU323956811">link</a></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Erweiterbare Desinfektionsvorrichtung</strong> -
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Erweiterbare Desinfektionsvorrichtung, umfassend: einen Hauptkörper, der eine umgekehrt U-förmige Basisplatte aufweist, wobei die umgekehrt U-förmige Basisplatte mit einer Öffnung versehen ist und jeweils eine Seitenplatte sich von zwei Seiten der umgekehrt U-förmigen Basisplatte nach außen erstreckt; und mindestens eine Desinfektionslampe, die in den auf zwei Seiten des Hauptkörpers befindlichen Seitenplatten angeordnet ist und eine Lichtemissionseinheit, eine Erfassungseinheit, eine Steuereinheit und eine Stromversorgungseinheit umfasst.</p></li>
|
||
</ul>
|
||
<img alt="embedded image" id="EMI-D00000"/>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE326402480">link</a></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Einfache Sterilisationsvorrichtung</strong> -
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Einfache Sterilisationsvorrichtung, mit einem Hauptkörper (11), der in Längsrichtung einen ersten Plattenabschnitt (111) und in Querrichtung einen zweiten Plattenabschnitt (112) aufweist, wobei der erste Plattenabschnitt (111) und der zweite Plattenabschnitt (112) L-förmig miteinander verbunden sind; und einer Sterilisationslampe (12), die an dem Hauptkörper (11) angeordnet ist und eine Lichtemissionseinheit (121), eine Sensoreinheit (122), eine Steuereinheit (123) und eine Stromeinheit (124) aufweist.</p></li>
|
||
</ul>
|
||
<img alt="embedded image" id="EMI-D00000"/>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE326402479">link</a></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Klemmarme aufweisende Desinfektionsvorrichtung</strong> -
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Klemmarme aufweisende Desinfektionsvorrichtung, umfassend: einen Hauptkörper; eine Desinfektionslampe, die im Hauptkörper angeordnet ist und eine Lichtemissionseinheit, eine Erfassungseinheit, eine Steuereinheit und eine Stromversorgungseinheit umfasst; einen Klemmabschnitt, der auf einer Seite des Hauptkörpers angeordnet ist, wobei der Klemmabschnitt zwei gegenüberliegende Greifbacken umfasst, wobei mindestens eine der beiden Greifbacken mit einer Schwenkachse versehen ist, wobei ein Klemmraum durch passgenaues Schließen der beiden Greifbacken entsteht und die beiden Greifbacken jeweils mit einem Durchgangsloch versehen sind; einen Befestigungsabschnitt, der durch die Durchgangslöcher der beiden Greifbacken hindurchgeführt ist;und ein Schild, das auf einer Seite des Klemmabschnitts angeordnet und mit einem Aufnahmeloch versehen ist.</p></li>
|
||
</ul>
|
||
<img alt="embedded image" id="EMI-D00000"/>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE326402478">link</a></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Aufhängbare Sterilisationsvorrichtung</strong> -
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Aufhängbare Sterilisationsvorrichtung, mit einem Hauptkörper (11); einer Sterilisationslampe (12), die an dem Hauptkörper (11) angeordnet ist und eine Lichtemissionseinheit (121), eine Sensoreinheit (122), eine Steuereinheit (123) und eine Stromeinheit (124) aufweist; einem Klemmabschnitt (13), der an einer Seite des Hautpkörpers (11) angeordnet ist und zwei gegenüberliegend angeordnete Klemmbacken (131) aufweist, wobei mindestens eine der beiden Klemmbacken (131) mit einem Achsbolzen (132) versehen ist, wobei die beiden Klemmbacken (131) beim Schließen einen Klemmraum (134) bilden, und wobei die beiden Klemmbacken (131) jeweils mit einem Durchgangsloch (135) versehen sind; und einem Befestigungselement (14), das durch die Durchgangslöcher (135) der beiden Klemmbacken (131) hindurchgeführt wird.</p></li>
|
||
</ul>
|
||
<img alt="embedded image" id="EMI-D00000"/>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE326402477">link</a></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Sterilisationsvorrichtung zur Verbesserung der Desinfektionswirkung</strong> -
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Sterilisationsvorrichtung zur Verbesserung der Desinfektionswirkung, umfassend: einen Hauptkörper, der eine erste Oberfläche, eine von der ersten Oberfläche abgewandte zweite Oberfläche und ein Aufnahmeloch aufweist, wobei die zwei Seiten des Hauptkörpers jeweils mit einem Durchgangsloch versehen sind, wobei die Durchgangslöcher mit dem Aufnahmeloch durchgängig verbunden sind; eine Desinfektionslampe, die auf der zweiten Oberfläche des Hauptkörpers angeordnet ist und eine Lichtemissionseinheit, eine Erfassungseinheit, eine Steuereinheit und eine Stromversorgungseinheit umfasst; und ein Befestigungsteil, das durch die Durchgangslöcher und das Aufnahmeloch des Hauptkörpers hindurchgeführt ist.</p></li>
|
||
</ul>
|
||
<img alt="embedded image" id="EMI-D00000"/>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE326402481">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>IMPROVEMENTS RELATED TO PARTICLE, INCLUDING SARS-CoV-2, DETECTION AND METHODS THEREFOR</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU323295937">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>DEEP LEARNING BASED SYSTEM FOR DETECTION OF COVID-19 DISEASE OF PATIENT AT INFECTION RISK</strong> - The present invention relates to Deep learning based system for detection of covid-19 disease of patient at infection risk. The objective of the present invention is to solve the problems in the prior art related to technologies of detection of covid-19 disease using CT scan image processing. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN324122821">link</a></p></li>
|
||
</ul>
|
||
|
||
|
||
<script>AOS.init();</script></body></html> |